No Data
No Data
CervoMed Inc. Reports Increased R&D Expenses Amid Ongoing Trials
CervoMed | 10-Q: Quarterly report
CervoMed 3Q Rev $1.94M >CRVO
CervoMed Reports Q3 EPS (55c), Consensus (41c)
CervoMed 3Q Loss/Shr 55c >CRVO
Express News | CervoMed Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
No Data
No Data
I Am 102927471 :